FDA Drug Approval Timeline: From IND Filing to Market Authorization
FDA does not publish one universal end-to-end timeline from discovery to approval for every drug. Early research, preclinical work, and clinical development vary widely by product and disease area. The clearest FDA-defined clocks are later in the process: an IND generally may proceed 30 days after FDA receives it unless the agency places the study on clinical hold, and the review goal for a marketing application is generally 10 months for standard review or 6 months for priority review.
Key Takeaways
Key Takeaways
- FDA does not publish a single universal discovery-to-approval duration that applies to all products
- The clearest FDA-defined timelines are the 30-day IND safety review and the 10-month or 6-month NDA/BLA review goals for standard and priority review
- Expedited programs can change development and review sequencing, but their effect on total calendar time is product specific
- An IND becomes effective 30 days after FDA receipt unless a clinical hold is placed; there is no formal IND "approval"
- The FDA drug approval timeline is best understood as a sequence of regulatory stages, not a single dependable average. FDA describes the drug-development process in five steps: discovery and development, preclinical research, clinical research, FDA review, and post-market safety monitoring.
- Understanding each stage of this timeline is critical for regulatory professionals planning submissions, executives setting milestones, and investors evaluating development risk. Every phase has defined regulatory touchpoints, and missteps at any stage can add months or years to the overall timeline.
- In this guide, you will learn:
- The complete FDA drug approval timeline from preclinical development through post-market
- Which parts of the process have defined FDA clocks and which do not
- How the NDA/BLA review process works and how long each phase takes
- The impact of accelerated programs (Fast Track, Breakthrough, Accelerated Approval, Priority Review) on timelines
- Pre-submission milestones that can prevent delays
- ---
Overview: The Complete Drug Development Timeline
The FDA drug approval process consists of five major phases, but only some parts have a defined FDA review clock:
| Phase | Activities | Timing |
|---|---|---|
| Preclinical | Discovery, lead optimization, laboratory and animal studies, IND preparation | Variable |
| Phase 1 | Initial human safety and pharmacology studies | Variable |
| Phase 2 | Exploratory efficacy, dose finding, and safety studies | Variable |
| Phase 3 | Pivotal studies supporting marketing application | Variable |
| NDA/BLA Review | Filing review, multidisciplinary review, inspections, action | 10 months standard or 6 months priority from filing date |
According to FDA, of every 5,000-10,000 compounds screened in preclinical testing, approximately 250 enter clinical trials, and only 1 receives FDA approval (FDA, "The Drug Development Process," 2023).
Stage 1: Preclinical Development
Preclinical development encompasses all research conducted before a drug is tested in humans. This phase is governed by Good Laboratory Practice (GLP) regulations under 21 CFR Part 58.
Key Preclinical Activities
| Activity | Purpose | Regulatory Requirement |
|---|---|---|
| Drug discovery and screening | Identify candidate compounds | None (pre-regulatory) |
| Lead optimization | Improve potency, selectivity, and ADME profile | None |
| In vitro pharmacology | Characterize mechanism and pharmacology | Product specific |
| In vivo animal studies | Generate safety, toxicology, and PK information | GLP where applicable under 21 CFR Part 58 |
| Formulation and CMC development | Develop clinical material and manufacturing controls | 21 CFR Parts 210 and 211 for clinical supply as applicable |
IND-Enabling Studies
Before filing an Investigational New Drug (IND) application, sponsors must complete IND-enabling studies as outlined in FDA Guidance, "Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals" (ICH M3(R2)):
- Single-dose toxicology in two species (rodent and non-rodent)
- Repeat-dose toxicology with duration supporting proposed clinical trial length
- Genotoxicity studies (in vitro and in vivo per ICH S2(R1))
- Safety pharmacology (cardiovascular, respiratory, CNS per ICH S7A/S7B)
- ADME studies (absorption, distribution, metabolism, excretion)
Stage 2: IND Application and Clinical Trial Authorization
Filing the IND Application
The IND application, filed under 21 CFR 312, is the regulatory gateway to human clinical testing. The IND must contain sufficient preclinical data to justify the proposed clinical investigation.
IND content requirements (21 CFR 312.23):
| IND Section | Contents |
|---|---|
| Form FDA 1571 | Cover sheet with sponsor, investigator, and protocol information |
| Table of contents | Complete listing of all submitted documents |
| Introductory statement | Brief overview of drug and clinical plan |
| General investigational plan | Summary of planned Phase 1-3 studies |
| Investigator's brochure | All known pharmacology, toxicology, clinical data |
| Clinical protocol(s) | Detailed Phase 1 protocol |
| Chemistry, Manufacturing, Controls | Drug substance and product characterization, manufacturing |
| Pharmacology/Toxicology | GLP nonclinical study reports |
| Previous human experience | Any prior clinical data (if applicable) |
IND Review Timeline
| Milestone | Timeline | Action |
|---|---|---|
| IND submission (Day 0) | - | FDA receives IND via ESG |
| FDA safety review | Days 1-30 | FDA reviews for subject safety |
| IND effective date | Day 30 | If FDA does not place clinical hold, IND becomes effective |
| Clinical hold (if issued) | Within 30 days | FDA identifies safety concern; trial cannot begin |
| Pre-IND meeting (optional) | Before submission | Type B meeting with FDA (per FDA Guidance on Formal Meetings) |
“Key Point: An IND goes into effect 30 calendar days after FDA receives it, unless FDA places a clinical hold under 21 CFR 312.42. There is no formal "approval" of an IND; the absence of a hold constitutes authorization to proceed.
Pre-IND Meeting
Under FDA Guidance, "Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products" (December 2023), a Pre-IND meeting (Type B meeting) allows sponsors to discuss:
- Proposed clinical trial design
- Nonclinical study adequacy
- CMC readiness
- Biomarker strategy
FDA commits to scheduling Pre-IND meetings within 60 calendar days of the meeting request and providing written feedback.
Stage 3: Clinical Trials
Clinical trials represent the longest and most expensive phase of drug development. The three traditional phases (plus Phase 4 post-approval) are defined in 21 CFR 312.21.
Phase 1: Safety and Pharmacokinetics
| Parameter | Typical Values |
|---|---|
| Objective | Safety, tolerability, pharmacokinetics, pharmacodynamics |
| Population | 20-80 healthy volunteers (or patients for oncology/rare disease) |
| Design | Single ascending dose (SAD), multiple ascending dose (MAD), food effect |
| Regulatory framework | 21 CFR 312.21(a) |
Phase 1 trials establish:
- Maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D)
- Pharmacokinetic profile (absorption, distribution, metabolism, excretion)
- Preliminary safety and adverse event profile
- Drug-drug interaction potential
Phase 2: Efficacy and Dose Finding
| Parameter | Typical Values |
|---|---|
| Objective | Preliminary efficacy, dose-response, safety in target population |
| Population | 100-500 patients with target disease |
| Design | Randomized, controlled, often dose-ranging |
| Regulatory framework | 21 CFR 312.21(b) |
Phase 2 is often divided into:
- Phase 2a: Proof-of-concept (does the drug work at all?)
- Phase 2b: Dose-finding (what is the optimal dose?)
An End-of-Phase 2 (EOP2) meeting with FDA is often important to align on Phase 3 trial design, endpoints, and the overall evidentiary plan before pivotal studies begin.
Phase 3: Confirmatory Trials
| Parameter | Typical Values |
|---|---|
| Objective | Confirm efficacy, characterize safety profile for labeling |
| Population | 300-3,000+ patients (sometimes 10,000+ for chronic conditions) |
| Design | Randomized, double-blind, controlled, often multi-center global |
| Regulatory framework | 21 CFR 312.21(c) |
Phase 3 trials are "pivotal" studies that form the primary evidence basis for the NDA/BLA submission. FDA typically requires:
- At least two adequate and well-controlled studies (21 CFR 314.126), though a single study with strong evidence may suffice in certain cases (FDA Guidance, "Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products," May 1998)
- Safety database adequate to characterize adverse events (ICH E1 recommends 1,500 patients for chronic conditions)
- Special populations (elderly, pediatric, hepatic/renal impairment) as applicable
FDA does not assign a universal calendar length to any clinical phase. Enrollment, endpoint maturity, follow-up duration, and manufacturing readiness can all materially change the timeline.
Stage 4: NDA/BLA Preparation and Submission
Pre-Submission Activities
Before filing the NDA or BLA, sponsors typically complete the clinical study reports, assemble the eCTD, prepare integrated summaries, finalize Module 3 CMC documentation, and align with FDA on the content and format of the application. FDA does not prescribe one universal project timeline for these internal preparation steps.
Pre-NDA/Pre-BLA Meeting
The Pre-NDA or Pre-BLA meeting (Type B) is one of the most important regulatory interactions in the approval timeline. Under FDA Guidance on Formal Meetings, FDA commits to:
- Granting the meeting within 60 calendar days of the meeting request
- Providing written responses to the sponsor's questions
Key topics for the Pre-NDA/Pre-BLA meeting:
- Adequacy of the clinical and nonclinical data package
- Proposed labeling and indication wording
- REMS (Risk Evaluation and Mitigation Strategy) requirements
- Manufacturing and CMC readiness
- Planned submission format and content
NDA vs BLA: Which Application?
| Criterion | NDA (21 CFR 314) | BLA (42 USC 262) |
|---|---|---|
| Product type | Small molecule drugs | Biological products |
| Reviewing center | CDER | CDER or CBER |
| eCTD format | Required | Required |
| PDUFA timeline | Same | Same |
| Manufacturing | Process-based approval | Facility-specific license |
The NDA/BLA Submission
The NDA (21 CFR 314.50) or BLA (21 CFR 601.2) is submitted in eCTD format through FDA's Electronic Submissions Gateway. The submission comprises five modules per ICH M4:
| Module | Content | Key Sections |
|---|---|---|
| Module 1 | Regional administrative | FDA forms, cover letter, patent info, labeling |
| Module 2 | Summaries | Quality Overall Summary, Nonclinical/Clinical Overviews |
| Module 3 | Quality (CMC) | Drug substance, drug product, manufacturing |
| Module 4 | Nonclinical | Pharmacology, PK, toxicology study reports |
| Module 5 | Clinical | Clinical study reports, individual patient data |
Stage 5: FDA Review Process
The FDA review process from submission to action follows a structured sequence, but not every internal milestone is fixed for every application.
FDA Review Timeline
| Phase | Timing | Activities |
|---|---|---|
| Receipt and acknowledgment | Submission day | FDA receives the eCTD submission |
| Filing review | First 60 days | Completeness assessment and filing decision under 21 CFR 314.101 |
| Substantive review | Review clock | Clinical, pharmacology, CMC, statistical, and labeling review |
| Inspections and facilities review | Product specific | FDA may inspect manufacturing or clinical sites as needed |
| Advisory Committee | If requested | Independent external advice for selected applications |
| Action | By goal date unless extended | Approval, Complete Response Letter, or extension for a major amendment |
Review Types and Timelines
| Review Type | Timeline | Eligibility | Regulatory Basis |
|---|---|---|---|
| Standard | 10 months from filing | Default review designation | PDUFA review goals |
| Priority | 6 months from filing | Significant improvement in safety or effectiveness | PDUFA review goals |
| Real-Time Oncology Review (RTOR) | Variable | Select oncology applications | FDA pilot or program criteria |
Possible FDA Actions at PDUFA Date
| Action | Meaning | Next Steps |
|---|---|---|
| Approval Letter | Drug approved for marketing | Launch preparation, PMR/PMC compliance |
| Complete Response Letter | Deficiencies identified, not approved | Address deficiencies, resubmit (Class 1 or 2) |
| Major Amendment extension | 3-month PDUFA date extension | Respond to FDA request, await new date |
Accelerated Programs: Impact on the Timeline
FDA offers four distinct expedited programs that can significantly compress portions of the development and review timeline. These programs are codified in the FD&C Act and detailed in FDA Guidance, "Expedited Programs for Serious Conditions - Drugs and Biologics" (2014, with subsequent updates).
Fast Track Designation (FD&C Act Section 506(b))
| Feature | Details |
|---|---|
| Eligibility | Serious condition + potential to address unmet medical need |
| Timeline impact | Enables rolling review (submit completed sections before full NDA/BLA) |
| Request timing | Any time during development (typically during or after Phase 1) |
| Additional benefit | More frequent FDA meetings, written communication on trial design |
Breakthrough Therapy Designation (FD&C Act Section 506(a))
| Feature | Details |
|---|---|
| Eligibility | Serious condition + preliminary evidence of substantial improvement |
| Timeline impact | Intensive FDA guidance, organizational commitment, rolling review |
| Request timing | After clinical evidence of substantial improvement (typically Phase 2) |
| Additional benefit | Senior FDA management involvement, cross-disciplinary review |
Accelerated Approval (21 CFR 314 Subpart H / 21 CFR 601 Subpart E)
| Feature | Details |
|---|---|
| Eligibility | Serious condition + meaningful therapeutic benefit + surrogate endpoint |
| Timeline impact | Approval based on surrogate endpoint rather than clinical outcome |
| Request timing | Before Phase 3 design (to confirm FDA acceptance of surrogate) |
| Requirement | Post-marketing confirmatory study required (FDORA 2022 strengthened enforcement) |
Priority Review (PDUFA VII Commitment Letter)
| Feature | Details |
|---|---|
| Eligibility | Significant improvement in safety/effectiveness of serious condition |
| Timeline impact | 6-month review vs 10-month standard |
| Request timing | With NDA/BLA submission or during filing review |
| Note | Can be combined with Fast Track, Breakthrough, or Accelerated Approval |
Combined Program Impact
These programs can overlap, but they affect different parts of development and review. The size of any calendar-time benefit is product specific and depends on the evidence package, trial design, endpoint strategy, manufacturing readiness, and whether FDA grants the requested designation.
Post-Approval: Stage 6 (Ongoing)
Approval is not the end of the regulatory timeline. Post-approval commitments extend indefinitely.
Post-Marketing Requirements
| Requirement | Basis | Timeline |
|---|---|---|
| PMR (Post-Marketing Requirement) | FD&C Act Section 505(o)(3) | Defined schedule, FDA-enforceable |
| PMC (Post-Marketing Commitment) | Voluntary agreement | Negotiated timeline |
| Phase 4 studies | Often part of PMR/PMC | 2-5+ years |
| REMS compliance | FD&C Act Section 505-1 | Duration of marketing |
| Annual reports | 21 CFR 314.81(b)(2) | Within 60 days of anniversary |
| Safety reporting | 21 CFR 314.80/314.98 | 15-day (serious) or periodic |
| Labeling updates | 21 CFR 314.70 | As safety information evolves |
Timeline Summary: Putting It All Together
For planning purposes, the safest statement is:
- Discovery, preclinical work, and clinical development are highly variable and FDA does not publish one universal total calendar figure for all products.
- The IND stage has a clear statutory clock: the study may proceed 30 days after FDA receipt unless FDA imposes a clinical hold.
- The marketing-application stage has the clearest review goals: 10 months for standard review and 6 months for priority review from the filing date.
References
There is no single FDA-published end-to-end timeline that applies to every development program. The parts FDA defines most clearly are the 30-day IND safety review and the 10-month or 6-month NDA/BLA review goals for standard and priority review.